GSA Capital Partners LLP Boosts Position in Cue Biopharma, Inc. (NASDAQ:CUE)

GSA Capital Partners LLP lifted its position in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 5.1% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 291,663 shares of the company’s stock after purchasing an additional 14,104 shares during the quarter. GSA Capital Partners LLP’s holdings in Cue Biopharma were worth $221,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Sigma Planning Corp grew its position in shares of Cue Biopharma by 50.9% in the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock worth $304,000 after acquiring an additional 135,295 shares in the last quarter. Good Life Advisors LLC grew its holdings in Cue Biopharma by 23.1% during the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after acquiring an additional 75,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Cue Biopharma during the second quarter worth about $66,000. Finally, Vanguard Group Inc. raised its position in Cue Biopharma by 7.1% in the first quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock worth $4,316,000 after acquiring an additional 150,457 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus decreased their target price on Cue Biopharma from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cue Biopharma currently has a consensus rating of “Buy” and a consensus price target of $5.00.

Cue Biopharma Trading Down 1.0 %

Shares of CUE stock opened at $1.02 on Monday. Cue Biopharma, Inc. has a 12 month low of $0.45 and a 12 month high of $3.25. The company has a market cap of $64.62 million, a PE ratio of -1.13 and a beta of 1.80. The business’s 50 day moving average is $1.19 and its two-hundred day moving average is $1.13. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.